Yazılar

Neuralink Plans High-Volume Brain Implant Production by 2026, Musk Says

/in /tarafından

Neuralink will begin “high-volume production” of its brain–computer interface implants and shift to a fully automated surgical procedure in 2026, according to a statement by Elon Musk.

Musk shared the update on the social media platform X on Wednesday. Neuralink did not immediately respond to a request for comment from Reuters.

The Neuralink implant is designed to help people with neurological conditions such as spinal cord injuries by enabling direct communication between the brain and computers. The company’s first patient has demonstrated the ability to play video games, browse the internet, post on social media and control a laptop cursor using only their thoughts.

Neuralink began human trials of its brain implant technology in 2024, after resolving safety concerns raised by the U.S. Food and Drug Administration. The regulator had initially rejected the company’s application in 2022, citing risks related to the device and surgical process.

In September, Neuralink said that 12 people worldwide with severe paralysis had received its implants and were using them to control both digital and physical tools through neural signals. The company has positioned the technology as a potential breakthrough for restoring independence to patients with limited mobility.

The startup has also attracted strong investor interest. In June, Neuralink raised $650 million in a funding round, providing capital to scale manufacturing, expand clinical trials and advance automation plans ahead of its targeted 2026 production push.

FDA clears Apple Watch hypertension detection feature

/in /tarafından

The U.S. Food and Drug Administration (FDA) has given Apple the green light to introduce a hypertension detection feature on its latest smartwatch models. The approval marks another step in Apple’s push to expand its footprint in digital health technology.

Apple showcased the feature during its September 9 launch event, alongside a new iPhone lineup. The feature will be available later this month on the Apple Watch Series 9, Series 10, Series 11, and the Ultra 2 and Ultra 3 models, with plans to roll out in 150 countries and regions, including the U.S. and EU.

Using the watch’s optical heart sensor, the system analyzes how blood vessels respond to heartbeats. Instead of taking single-time readings like a traditional cuff monitor, the algorithm works passively, reviewing data across 30-day periods. If it finds consistent signs of hypertension, the watch sends the user an alert.

Apple emphasized the tool is not meant to diagnose or capture every case of high blood pressure, but could warn an estimated one million users worldwide.

Bloomberg had earlier reported the feature would begin rolling out as soon as next week. Apple has not commented further on the timeline.

FDA to Review AI-Powered Mental Health Devices in November Advisory Panel

/in /tarafından

The U.S. Food and Drug Administration (FDA) announced it will convene its Digital Health Advisory Committee (DHAC) on November 6 to evaluate the growing category of AI-enabled digital mental health tools.

The meeting will explore how technologies such as chatbots, virtual therapists, and digital therapeutics could help bridge the nation’s mental health care gap, while also assessing the risks of safety, efficacy, and oversight.

Why It Matters

The U.S. faces a shortage of mental health professionals, and AI-driven platforms promise scalability, accessibility, and rapid intervention. But the speed of innovation has left regulators searching for frameworks to ensure these devices are trustworthy and clinically sound.

FDA’s Approach

  • The DHAC will advise the agency on regulatory pathways for AI/ML tools, remote monitoring, digital therapeutics, and medical device software.

  • The panel discussion is expected to help the FDA identify key areas of concern such as data privacy, bias in algorithms, and standards for clinical validation.

  • The FDA has already begun experimenting with AI in its review processes, reflecting its broader shift toward digital oversight.

Next Steps

  • The FDA has opened a public docket for comments ahead of the session.

  • Supporting materials will be made available at least two business days before the meeting.

The November discussion could shape how future AI mental health devices are classified, monitored, and approved in the U.S., setting an early precedent for regulation in this rapidly expanding sector.